Sartorius is a Germany-based life science group that develops and supplies bioprocessing technologies and laboratory products for the biopharmaceutical industry and research laboratories worldwide. Headquartered in Göttingen, the company operates through two segments: Bioprocess Solutions, centered on manufacturing of biologics and advanced therapies, and Lab Products & Services, focused on laboratory instrumentation and consumables. Its French-listed subgroup, Sartorius Stedim Biotech, concentrates on bioprocess technologies.
The portfolio spans single-use bioreactors and fermenters, mixing and fluid-management systems, filtration and membrane technologies, process analytics, and chromatography equipment, as well as laboratory balances, pipettes, purification systems, and cell analysis tools. Sartorius supports development and manufacture of vaccines, monoclonal antibodies, cell and gene therapies, and other biologics, providing equipment, consumables, and digital solutions that help scale processes from discovery to commercial production.
None yet. When a new project in the record names Sartorius as owner, partner or investor, it shows here.
Sartorius acquires Albumedix for £415M, adding recombinant albumin solutions to its portfolio. This enhances cell culture media and vaccine production capabilities. Transaction closes Q3 2022.
